Oxidative stress in Huntington's disease

Brain Pathology

Volumn 9, Issue 1, 1999, Pages 147-163

  Browne, Susan E ^a,e   Ferrante, Robert J ^b,c   Beal, M Flint ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; HEME OXYGENASE; HUNTINGTIN; MALONALDEHYDE; MUTANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL INCLUSION; CONFERENCE PAPER; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; RAT;

EID: 0032903802     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.1999.tb00216.x     Document Type: Conference Paper

References (105)

1. Albin RL, Reiner A, Anderson KD, Penney JB, Young AB (1990) Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol 27: 357-365
2. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366-375
3. Albin RL, Greenamyre JT (1992) Alternative excitotoxic hypotheses. Neurology 42: 733-738
4. Alexander GE, Crutcher MD (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13: 266-271
5. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA et al. (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4: 398-403
6. Beal MF. (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illness? Ann Neurol 31: 119-130
7. Beal MF (1994) Neurochemistry and toxin models in Huntington's disease. Curr Op Neurol 7: 542-547
8. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321: 168-171
9. Beal MF, Ellison DW, Mazurek MF, Swartz KJ, Malloy JR, Bird ED, Martin JB (1988) A detailed examination of substance P in pathologically graded cases of Huntington's disease. J Neurol Sci 84: 51-61
10. Beal MF, Swartz KJ, Hyman BT, Storey E. Finn SF and Koroshetz W. (1991b) Aminooxyacetic acid results in excitotoxin lesions by a novel indirect mechanism. J Neurochem 57: 1068-1073
11. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hymen BT (1993a) Neurochemical and histologic characterization of excitotoxic lesions produced by mitochondrial toxin 3-nitropropionic acid. J Neurosci 13: 4181-4192
12. Beal MF, Hyman BT and Koroshetz W. (1993b) Do defects in mitochondrial energy metabolism underlie the pathology of neu rodegenerative diseases? Trends Neurosci 16: 125-131
13. Beal MF, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB. (1994) Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 36: 882-888
14. Beal MF, Ferrante RJ, Henshaw R, Matthews RT, Chan PH, Kowall NW, Epstein CJ, Schulz JB (1995) 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice. J Neurochem 65: 919-922
15. Blaustein MP (1988) Calcium transport and buffering in neurons. Trends Neurosci 11: 438-443
16. Bolanos JP, Heales SJR, Land JM, Clark, JB (1995) Effect of peroxynitrite on the mitochondrial respiratory chain: Differential susceptibility of neurones and astrocytes in primary culture. J Neurochem 64: 1965-1972
17. Braak H, Braak E (1992) Allocortical involvement in Huntington's disease. Neuropathol App Neurobiol 18: 539-547
18. Brennan WA, Bird ED, Aprille JR. (1985) Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 44: 1948-1950
19. Bresolin N, Bet L, Binda A, Moggio M, Comi G, Nador F, Ferrante C, Carenzi A, Scarlato G (1988) Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology 38: 892-899
20. Brouillet EP, Jekins BG, Hyman BT, Ferrante, RJ, Kowall NW, Srivastava R, Samanta-Roy D, Rosen BR, Beal MF (1993) Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 60: 356-359
21. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 92: 7105-7109
22. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MMK, Bird ED, Beat MF (1997) Oxidative damage and metabolic dysfunction in Huntington's Disease: Selective vulnerability of the basal ganglia. Annals Neurol 41: 646-653
23. Browne SE, Beal MF (1994) Oxidative damage and mitochondrial dysfunction in neuro-degenerative diseases. Biochem Soc Trans 22: 1002-1006
24. Burke JR, Enghild JJ, Martin ME, Jou Y-S, Myers RM, Roses AD, Vance VM, Strittmatter WJ (1996) Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nature Med 2: 347-350
25. Butterworth J, Yates CM, Reynolds GP (1985) Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase, and α-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J Neurol Sci 67: 161-171
26. Butterworth NJ, Williams L, Bullock JY, Love DR, Faull RLM, Dragunow M, (1998) Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neurosci 87: 49-53
27. Calabresi P, Centonze D, Pisani A, Sancesario G, Gubellini P, Marfia GA, Bernardi G (1998) Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann Neurol 43: 586-597
28. Choi DW (1988) Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci 11: 465-469
29. Cooper AJL, Sheu K-FR, Burke JR, Onodera O, Strittmatter WJ, Roses AD, Blass JP. (1997) Transglutaminase-catalyzed inactivation of glyceralde-hyde 3-phosphate dehydrogenase and a-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. Proc Nati Acad Sci USA. 94: 12604-12609
30. Davies SW, Turmaine M, Cozens B, DiFiglia M, Sharp A, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates G. (1997) Formation of neuronal intranuclear inclusions (NII) underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537-548.
31. de la Monte SM, Vonsattel JP, Richardson Jr EP (1988) Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropath Exp Neurol 47: 516-525
32. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, Martin E, Vonsattel J-P, Carraway R, Reeves SA, Boyce FM, Aronin N (1995) Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14: 1075-1081
33. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel J-P, Aronin N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993
34. Driggers WJ, Holmquist GP, LeDoux SP, Wilson GL (1997) Mapping frequencies of endogenous oxidative damage and the kinetic response to oxidative stress in a region of rat mtDNA. Nucleic Acids Res 25: 4362-9
35. Dugan LL, Sensi SL, Canzoniero LM, Handran SD, Rothman SM, Lin TS, Goldberg MP, Choi DW (1995) Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J Neurosci 15: 6377-6388
36. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, Folstein S, Ross C, Franz M, Abbott M, et al (1993) Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 4: 387-92
37. Duyao MP, Auerbach AB, Persichetti F, Barnes GT, McNeil SM, Ge P, Vonsattel J-P, Gusella JF, Joyner AL, MacDonald ME (1995) Inactivation of the mouse Huntington's disease gene homolog (Hdh ). Science 269: 407-410
38. +: implications for neurodegeneration. J Neurochem 63: 584-91
39. Ferrante RJ, Gutekunst C-A, Persichetti F, McNeil SM, Kowall NW, Gusella JF, MacDonald ME, Beal MF, Hersch SM (1997) Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J Neurosci 17: 3052-3063
40. Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, Richardson EP (1987) Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J Neuropath Exp Neurol 46: 12-27
41. Ferrante RJ, Kowall NW, Hersch SM, Brown rh, Beal MF (1996) Immunohistochemical localization of markers of oxidative injury in Huntington's disease. Soc Neurosci 22: 92.5
42. Fraga CG, Shigenaga MK, Park J-W, Degan P, Ames BN (1990) Oxidative damage to DNA during aging: 8-hydroxy-2'-deoxyguanosine in rat organ DNA and urine. Proc Natl Acad Sci USA 87: 4533-4537
43. Furtado S, Suchowersky O, Rewcastle B, Graham L, Klimek ML, Garber A. (1996) Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol 39: 132-136
44. Goebel HH, Heipertz R, Scholz W, Iqbal K, Tellez-Nagel I. (1978) Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology 28: 23-31
45. Gonzalez-Zulueta M, Ensz LM, Mukhina G, Lebovitz RM, Zwacka RM, Engelhardt JF, Oberley LW, Dawson VL, Dawson TM. (1998) Manganese superoxide dismutase protects nNOS neurons from NMDA and nitric oxidemediated neurotoxicity. J Neurosci 18: 2040-2055
46. Graveland GA, Williams RS, DiFiglia M (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227: 770-773 n
47. Graybiel AM, Aosaki T, Flaherty AW, Kimura M (1994) The basal ganglia and adaptive motor control. Science 265: 1826-1831
48. Greene JG, Porter RH, Eller RV, Greenamyre JT (1993) Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J Neurochem 61: 1151-1154
49. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AHV (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39: 385-389
50. Gutekunst C-A, Levey AI, Heilman CJ, Whaley WL, Yi H, Nash NR, Rees HD, Madden JJ, Hersch SM (1995) Identification and localization of huntingtin in brain and human lympho-blastoid cell lines with anti-fusion protein antibodies. Proc Nati Acad Sci USA 92: 8710-8714
51. Hemmer W, Wallimann T. (1993) Functional aspects of creatine kinase in brain. Dev Neurosci 15: 249-260
52. Ihara Y, Namba R, Kuroda S, Sato T, Shirabe T (1989) Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy withcoenzyme Q10 and idebenone. J Neurol Sci 90: 263-271
53. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, Beckman JS (1992) Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 298: 431-7
54. Jackson GR, Salecker I, Schulze KL, Dong X, Yao X, Arnheim N, Faber P, MacDonald ME, Zipursky SL (1998) Age- and polyglutamine length-dependent degeneration of drosophila photoreceptor neurons induced by human huntingtin transgenes. Soc Neurosci 24: 205.2
55. Jenkins BG, Koroshetz W, Beal MF, Rosen B (1993) Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy. Neurology 43: 2689-2695
56. Jenkins BG, Rosas HD, Chen Y-Cl, Makabe T, Myers R, MacDonald M, Rosen BR, Beal MF, Koroshetz WJ (1998) 1H-NMR spectroscopy studies of Huntington's disease. Neurology 50: 1357-1365
57. Koh J-Y, Peters S, Choi DW (1986) Neurons containing NADPH-diaphorase are selectively resistant to quinolinate toxicity. Science 234: 73-76
58. 10. Ann Neurol 41: 160-165
59. Kuemmerle S, Klein AM, Gutekunst C-A, Li X-J, Li S-H, Hersch SM, Ferrante R (1998) Distribution of huntingtin aggregation in spared and vulnerable neurons in Huntington's disease. Soc Neurosci 24: 380.14
60. Kuhl DE, Markham CH, Metter EJ, Riege WH, Phelps ME, Mazziotta JC (1985) Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease. Research Publications - Association for Research in Nervous and Mental Disease 63: 199-209
61. Kuwert T, Lange HW, Langer K-J, Herzog H, Aulich A, Feinendegen LE (1990) Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 113: 1405-1423
62. Landwehrmeyer GB, McNeil SM, Dure LS, Ge P, Aizawa H, Huang Q, Ambrose CM, Duyao MP, Bird ED, Bonilla E, de Young M, Avila-Gonzales AJ, Wexler NS, DiFiglia M, Gusella JF, MacDonald ME, Penney JB, Young AB and Vonsattel J-P (1995) Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals. Ann Neurol 37: 218-230
63. Li X-J, Li S-H, Sharp AH, Nucifora FC Jr., Schilling G, Lanahan A, Worley P, Snyder SH, Ross CA (1995) Huntingtin-associated protein enriched in brain with implicatins for pathology. Nature 378: 398-402
64. Linnane AW, Marzuki S, Ozawa T, Tanaka M (1989) Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet 1(8639): 642-645
65. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M. (1990) 3-nitropropionic acid: exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18: 492-498
66. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates G (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506
67. Marnett LJ, Buck J, Tuttle MA, Basu AK, Bull AW (1985) Distribution and oxidation of malondialdehyde in mice. Prostaglandins 30: 241-254
68. Matsumara M, Tremblay L, Richard H, Filion M (1995) Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neurosci 65: 59-70
69. Matthews RT, Yang L, Jenkins BJ, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF (1998) Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 18: 156-163
70. Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, Huffman JM, Kuhl DE, Lanto AB, Wapenski JA, Markham CH (1987) Reduced cerebral glucose metabolism in asymptomatic patients at risk for Huntington's disease. New Eng J Med 316: 357-362
71. May PC, Gray PN (1985) The mechanism of glutamate-induced degeneration of cultured Huntington's disease and control fibroblasts. J Neurol Sci 70: 101-112
72. Moulder KL, Onodera O, Burke J, Strittmatter WJ, Johnson Jr EM (1998) Polyglutamine containing proteins produce length-dependent aggregation and death in cultured cerebellar granule cells. Soc Neurosci 24: 379.5
73. Myers RH, Vonsattel JP, Paskevich PA, Kiely DK, Stevens TJ, Cupples LA, Richardson EP Jr, Bird ED (1991) Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol. 50: 729-742
74. Nakano M, Gotoh S (1992) Accumulation of cardiac lipofuscin depends on metabolic rate of mammals. J Gerontol 47: B126-129
75. Nicoletti F, Bruno V, Copani A, Casabona G, Knopfel T (1996) Metabotropic glutamate receptors: A new target for the therapy of neurodegenerative disorders? Trends Neurosci 19: 267-271
76. Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988) Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 451: 205-212
77. O'Brien CF, Miller C, Goldblatt D, Welle S, Forbes G, Lipinski B, Panzik J, Peck R, Plumb S, Oakes D, Kurlan R, Shoulson I (1990) Extraneural metabolism in early Huntington's disease. Ann Neurol 28: 300-301
78. Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, Vig P, Mandel JL, Fischbeck KH, Pittman RN (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19: 333-344
79. Perutz M, Johnson T, Suzuki M, Finch JT (1994) Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA 91: 5355-5358
80. Portera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE (1995) Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 15: 3775-3787
81. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 85: 5733-5737
82. Richfield EK, Maguire-Zeiss KA, Cox C, Gilmore J, Voorn P (1995) Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients. Ann Neurol 37: 335-343
83. Ross CA (1995) When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. Neuron 15:493-6
84. Sapp E, Ge P, Aizawa H, Bird E, Penney J, Young AB, Vonsattel JP, DiFiglia M (1995) Evidence fora preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neurosci 64: 397-404
85. Saudou F, Finkbeiner S, Devys D, Greenberg ME (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55-66
86. Scherzinger E, Kurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, BatesGP, Davies SW, Lehrach H, Wanker EE (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like aggregates in vitro and in vivo. Cell 90: 549-558
87. Schulz JB, Henshaw DR, Jenkins BG, Ferrante RJ, Kowall NW, Rosen BR and Beal MF (1994) 3-Acetylpyridine produces age-dependent excitotoxic lesions in rat striatum. J Cereb Blood Flow Metab 14: 1024-1029
88. Schulz JB, Henshaw DR, MacGarvey U and Beal MF. (1996a) Involvement of oxidative stress in 3-nitropropionic acid neurotoxicity. Neurochem Intl 29: 167-171
89. Schulz JB, Matthews RT, Henshaw DR, Beal MF (1996b) Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neurosci 71: 1043-1048
90. Sharp NH, Loev SJ, Schilling G, Li S-H, Li X-J, Bao J, Wagster MV, Kotzuk JA, Steiner JP, Lo A, Hedreen J, Sisodia S, Snyder SH, Dawson TM, Ryugo DK, Ross CA (1995) Widespread expression of the Huntington's disease gene (IT-15) protein product. Neuron 14: 1065-1074
91. Sohal RS, Marzabadi MR, Galaris D, Brunk UT (1989) Effect of ambient oxygen concentration on lipofuscin accumulation in cultured rat heart myocytes - a novel in vitro model of lipofuscinogenesis. Free Radic Biol Med 6: 23-30
92. Sotrel A, Paskevich PA, Kiely DK, Bird ED, Willimas RS, Myers RH (1991) Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology 41: 1117-1123
93. Stadtman ER (1992) Protein oxidation and aging. Science 257: 1220-1224
94. Tellez-Nagel I, Johnson AB, Terry RD (1995) Studies on brain biopsies of patients with Huntington's chorea. J Neuropathol Exp Neurol 33: 308-332
95. Terman A, Brunk UT (1998) Lipofuscin: mechanisms of formation and increase with age. APMIS 106: 265-276
96. Trottier Y, Devys D, Imbert G, Saudou F, An I, Lutz Y, Weber C, Agid Y, Hirsch EC, Mandel JL (1995) Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 10: 104-110
97. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome. Cell 72: 971-983
98. Uemera Y, Kowall NW, Beal MF (1990) Relative sparing of NADPH-diaphorase-somatostatin-neuropeptide Y neurons in ischemic gerbil striatum. Ann Neurol 27: 620-625
99. Vonsattel J-P, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP (1985) Neuropathological classification of Huntington's disease. J Neuropath Exp Neurol 44: 559-577
100. Vonsattel JPG, DiFiglia M (1998) Huntington Disease. J Neuropathol Exp Neurol 57: 369-384
101. Weeks RA, Harding AE, Brooks DJ (1996) Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 40: 49-54
102. White JK, Auerbach W, Duyao MP, Vonsattel J-P, Gusella JF, Joyner AL, MacDonald ME (1997) Huntingtin function is required for mouse brain development and is not impaired by the Huntington's disease CAG expansion mutation. Nat Genet 17: 404-410
103. Young AB, Greenamyre JT, Hollingsworth Z, Albin R, D'Amato C, Shoulson I, Penney JB (1988) NMDA receptor losses in putamen from patients with Huntington's disease. Science 241: 981-3
104. Zeevalk GD, Nicklas WJ (1991) Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition. J Pharm Exp Ther 257: 870-878
105. Zhang J, Dawson VL, Dawson TM, Snyder SH (1994) Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science 263: 687-689